Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Safety, Immunogenicity, and Efficacy Study of a UTI Vaccine in Adults
2024-519319-32-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial of GSKVX000000044501 in urinary tract infection (UTI) (6 arms), sponsored by GSK. Planned start Apr 2025; status: authorised.
02
Drugs
GSKVX000000044501
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2024-519319-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519319-32-00.